Avadel Pharmaceuticals PLC (AVDL)
17.66
-0.43
(-2.38%)
USD |
NASDAQ |
Apr 24, 16:00
17.66
0.00 (0.00%)
After-Hours: 20:00
Avadel Pharmaceuticals Research and Development Expense (Quarterly): 2.359M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.359M |
| September 30, 2023 | 2.849M |
| June 30, 2023 | 4.223M |
| March 31, 2023 | 3.83M |
| December 31, 2022 | 6.235M |
| September 30, 2022 | 2.933M |
| June 30, 2022 | 4.541M |
| March 31, 2022 | 6.991M |
| December 31, 2021 | 2.11M |
| September 30, 2021 | 4.38M |
| June 30, 2021 | 6.762M |
| March 31, 2021 | 3.852M |
| December 31, 2020 | 5.286M |
| September 30, 2020 | 5.569M |
| June 30, 2020 | 4.057M |
| March 31, 2020 | 5.53M |
| December 31, 2019 | 7.757M |
| September 30, 2019 | 7.539M |
| June 30, 2019 | 10.29M |
| March 31, 2019 | 7.329M |
| December 31, 2018 | 6.086M |
| September 30, 2018 | 11.40M |
| June 30, 2018 | 11.89M |
| March 31, 2018 | 9.951M |
| December 31, 2017 | 11.32M |
| Date | Value |
|---|---|
| September 30, 2017 | 8.095M |
| June 30, 2017 | 6.792M |
| March 31, 2017 | 7.206M |
| December 31, 2016 | 13.48M |
| September 30, 2016 | 8.143M |
| June 30, 2016 | 7.604M |
| March 31, 2016 | 5.388M |
| December 31, 2015 | 5.161M |
| September 30, 2015 | 7.221M |
| June 30, 2015 | 7.204M |
| March 31, 2015 | 6.022M |
| December 31, 2014 | -3.566M |
| September 30, 2014 | 7.028M |
| June 30, 2014 | 3.60M |
| March 31, 2014 | 3.944M |
| December 31, 2013 | -6.547M |
| September 30, 2013 | 6.68M |
| June 30, 2013 | 7.304M |
| March 31, 2013 | 8.529M |
| December 31, 2012 | -5.395M |
| September 30, 2012 | 6.246M |
| June 30, 2012 | 7.722M |
| March 31, 2012 | 5.985M |
| December 31, 2011 | 5.91M |
| September 30, 2011 | 5.475M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.11M
Minimum
Dec 2021
10.29M
Maximum
Jun 2019
5.110M
Average
4.541M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Trinity Biotech PLC | 1.169M |
| Medtronic PLC | 695.00M |
| Biophytis SA | -- |
| Jazz Pharmaceuticals PLC | 216.61M |
| DBV Technologies SA | 12.78M |